The Role of PARP Inhibitor Combination Therapy in Ovarian Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 May 22

PMID 37215065

Authors

Helen Hockings

Rowan E Miller

Affiliations

Soon will be listed here.

Abstract

The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients will receive PARPi at some point in their treatment pathway. The majority of this expanding population of patients eventually acquire resistance to PARPi, in addition to those with primary PARPi resistance. We discuss the rationale behind developing combination therapies, to work synergistically with PARPi and overcome mechanisms of resistance to restore drug sensitivity, and clinical evidence of their efficacy to date.

Citing Articles

Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity.

Kim J, Han J, Kwon J, Kim M Invest New Drugs. 2025; .

PMID: 39962008 DOI: 10.1007/s10637-025-01509-8.

Low expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer.

Qiu Z, Sigh D, Liu Y, Prasad C, Bean N, Yan C Theranostics. 2024; 14(19):7450-7469.

PMID: 39659585 PMC: 11626944. DOI: 10.7150/thno.96879.

Dual Targeting of CXCR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma.

Xie J, Barbolina M Cancers (Basel). 2024; 16(22).

PMID: 39594684 PMC: 11591600. DOI: 10.3390/cancers16223728.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Drew Y, Zenke F, Curtin N Nat Rev Drug Discov. 2024; 24(1):19-39.

PMID: 39533099 DOI: 10.1038/s41573-024-01060-w.

Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta‑analysis.

Huang X, Luo J, Gu L Oncol Lett. 2024; 29(1):36.

PMID: 39512502 PMC: 11542167. DOI: 10.3892/ol.2024.14782.

References

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Ciriello G, Miller M, Aksoy B, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10):1127-33. PMC: 4320046. DOI: 10.1038/ng.2762. View

Lord C, Ashworth A . Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013; 19(11):1381-8. DOI: 10.1038/nm.3369. View

Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A . Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014; 111(4):651-9. PMC: 4134498. DOI: 10.1038/bjc.2014.345. View

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019; 29(4):728-760. DOI: 10.1136/ijgc-2019-000308. View

Kehoe S, Hook J, Nankivell M, Jayson G, Kitchener H, Lopes T . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990):249-57. DOI: 10.1016/S0140-6736(14)62223-6. View

Bristow R, Hill R . Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-92. DOI: 10.1038/nrc2344. View

Dedes K, Wilkerson P, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho J . Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011; 10(8):1192-9. PMC: 3117132. DOI: 10.4161/cc.10.8.15273. View

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

10.

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim Y, Gris-Oliver A . RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018; 29(5):1203-1210. PMC: 5961353. DOI: 10.1093/annonc/mdy099. View

11.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

12.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

13.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J . PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23(14):3711-3720. PMC: 5511572. DOI: 10.1158/1078-0432.CCR-16-3215. View

14.

Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, Christensen R, Heitz F, Meirovitz M . A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum.... Int J Gynecol Cancer. 2020; 31(4):617-622. DOI: 10.1136/ijgc-2020-001633. View

15.

Rundle S, Bradbury A, Drew Y, Curtin N . Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017; 9(5). PMC: 5447951. DOI: 10.3390/cancers9050041. View

16.

Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S . Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers. Cancer Discov. 2020; 10(10):1528-1543. PMC: 7611385. DOI: 10.1158/2159-8290.CD-20-0163. View

17.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

18.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

19.

Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26(22):3785-90. DOI: 10.1200/JCO.2008.16.0812. View

20.

Oza A, Cibula D, Benzaquen A, Poole C, Mathijssen R, Sonke G . Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2014; 16(1):87-97. DOI: 10.1016/S1470-2045(14)71135-0. View